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1 Supplementary Figures
Supplementary Figure 1: Directed acyclic graph to illustrate the difference be-
tween total and direct effect in two scenarios: a) mediation effect, where the
risk factor X1 has a direct and an indirect effect via the mediator X2 on the
outcome Y and b) signalling cascade where the effect of X1 on the outcome is
entirely mediated by X2.
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Supplementary Figure 2: Genetic correlation between metabolite measurements
based on the n = 148 genetic variants used as instrumental variables.
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Supplementary Figure 3: Receiver operating characteristic (ROC) curve for
setting A including a small number of risk factors (d = 12) of which four are
true positive effects. Proportion of variance explained is set to 0.1 (left) 0.3
(middle) and 0.5 (right).
Supplementary Figure 4: Receiver operating characteristic (ROC) curve for
setting B including a small number of risk factors (d = 12) of which eight are
true positive effects (four postive and four negative effect direction). Proportion
of variance explained is set to 0.1 (left) 0.3 (middle) and 0.5 (right).
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Supplementary Figure 5: Boxplots of the causal effect estimates for setting A including a small number of risk factors (d = 12)
of which the first four are true positive effects. The true causal effects are marked in red. From top left to bottom right are
the competing approaches: IVW, MR-BMA, best model, Lars, Lasso, and Elastic Net. Proportion of variance explained is set
to 0.3.
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Supplementary Figure 6: Boxplots of the causal effect estimates for setting B including a small number of risk factors (d = 12)
of which the first four have a positive and final four have a negative causal effect. The true causal effects are marked in red.
From top left to bottom right are the competing approaches: IVW, MR-BMA, best model, Lars, Lasso, and Elastic Net.
Proportion of variance explained is set to 0.3.
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Supplementary Figure 7: Receiver operating characteristic (ROC) curve for
setting A including a large number of risk factors (d = 92) of which four are
true positive effects. Proportion of variance explained is set to 0.1 (left) 0.3
(middle) and 0.5 (right).
Supplementary Figure 8: Receiver operating characteristic (ROC) curve for
setting B including a large number of risk factors (d = 92) of which eight are
true positive effects (four postive and four negative effect direction). Proportion
of variance explained is set to 0.1 (left) 0.3 (middle) and 0.5 (right).
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Supplementary Figure 9: Boxplots of the causal effect estimates for setting A including a large number of risk factors (d = 92)
of which the first four are true positive effects. Risk factors 11 to 92 are omitted. The true causal effects are marked in
red. From top left to bottom right are the competing approaches: IVW, MR-BMA, best model, Lars, Lasso, and Elastic Net.
Proportion of variance explained is set to 0.3.
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Supplementary Figure 10: Boxplots of the causal effect estimates for setting B including a large number of risk factors (d = 92)
of which the first four have a positive and the final 4 have a negative causal effect. Risk factors 7 to 86 are omitted. The true
causal effects are marked in red. From top left to bottom right are the competing approaches: IVW, MR-BMA, best model,
Lars, Lasso, and Elastic Net. Proportion of variance explained is set to 0.3.
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Supplementary Figure 11: Genetic correlation between blood cell traits based
on the n = 2667 genetic variants used as instrumental variables.
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Supplementary Figure 12: Receiver operating characteristic (ROC) curve for
setting A including (d = 33) blood cell traits as risk factors of which four are
true positive effects. Proportion of variance explained is set to 0.1 (left) 0.3
(middle) and 0.5 (right).
Supplementary Figure 13: Receiver operating characteristic (ROC) curve for
setting B including (d = 33) blood cell traits as risk factors of which four have
true positive effect and another four have true negative effect. Proportion of
variance explained is set to 0.1 (left) 0.3 (middle) and 0.5 (right).
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Supplementary Figure 14: Boxplots of the causal effect estimates for setting A for the blood cell traits (d = 33), of which the
first four are true positive effects. The true causal effects are marked in red. From top left to bottom right are the competing
approaches: IVW, MR-BMA, best model and Lars, Lasso and Elastic Net (all tuned with cross-validation). Proportion of
variance explained is set to 0.3.
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Supplementary Figure 15: Boxplots of the causal effect estimates for setting B for the blood cell traits (d = 33), of which the
first four have a positive and the last four have a negative causal effect. The true causal effects are marked in red. From top
left to bottom right are the competing approaches: IVW, MR-BMA, best model and Lars, Lasso and Elastic Net (all tuned
with cross-validation). Proportion of variance explained is set to 0.3.
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Supplementary Figure 16: Diagnostic plots for all genetic variants (n = 148) 
showing the predicted associations with AMD (x-axis) based on model 2 (M2: 
LDL diameter (LDL.D) and TG in small VLDL (S.VLDL.TG)), model 3 (M3: 
LDL.D and Serum.TG), against the observed associations with AMD (y-axis). 
Model 1 including LDL diameter (LDL.D), and TG content in small HDL 
(S.HDL.TG) is shown in the main manuscript. The colour code shows: left) 
the q-statistic for outliers and right) Cook’s distance for the influential points. 
Any genetic variant with q-value larger than 10 or Cook’s distance larger than 
the median is marked by a label indicating the gene region.
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Supplementary Figure 17: Scatterplot for the final set of genetic variants (n =
145) plotting the association with A) XL.HDL.C and B) L.HDL.C on the x-
axis against the association with AMD on the y-axis after excluding the LIPC,
FUT2 and APOE gene regions. The model-averaged causal effect (MACE) of
each risk factor on AMD is marked in red.
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Supplementary Figure 18: Diagnostic plots for the final set of genetic variants
(n = 145) showing the predicted associations with AMD (x-axis) based on the
best individual model 1 (M1: XL.HDL.C), model 2 (M2: L.HDL.C), model
3 (M3: XL.HDL.C and XS.VLDL.TG against the observed associations with
AMD (y-axis). The colour code shows: left) the q-statistic for outliers and
right) Cook’s distance for the influential points. Any genetic variant with q-
value larger than 10 or Cook’s distance larger than the median is marked by
a label indicating the gene region. The LIPC, FUT2 and APOE gene regions
have been removed prior to this analysis.18
Supplementary Figure 19: Diagnostic plots for the final set of genetic variants
(n = 145) showing the predicted associations with AMD (x-axis) based on the
best individual model 4 (M4: IDL.TG and XL.HDL.C), model 5 (M5: HDL.D)
against the observed associations with AMD (y-axis). The colour code shows:
left) the q-statistic for outliers and right) Cook’s distance for the influential
points. Any genetic variant with q-value larger than 10 or Cook’s distance
larger than the median is marked by a label indicating the gene region. The
LIPC, FUT2 and APOE gene regions have been removed prior to this analysis.
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Scenario 1: NMR metabolites, d = 12 risk factors
Setting A Setting B
θ = 0.3 θ = 0 θ = 0.3 θ = −0.3 θ = 0
R2 0.1 0.3 0.5 0.1 0.3 0.5 0.1 0.3 0.5 0.1 0.3 0.5 0.1 0.3 0.5
IVW 0.0014 -0.0099 0.0011 -0.0023 0.0042 -0.0007 -0.0129 0.0012 -0.0015 0.0063 0.0005 -0.0031 0.0072 0.0035 0.0066
Lars -0.1496 -0.1054 -0.0743 0.0143 0.0179 0.0142 -0.1742 -0.1231 -0.0892 0.1728 0.1230 0.0904 0.0014 -0.0001 -0.0011
Lasso -0.1337 -0.0864 -0.0628 0.0241 0.0235 0.0195 -0.1678 -0.1030 -0.0730 0.1652 0.1038 0.0706 0.0010 -0.0009 0.0025
Elastic Net -0.1229 -0.0849 -0.0641 0.0263 0.0247 0.0213 -0.1470 -0.0961 -0.0664 0.1445 0.0962 0.0646 0.0000 0.0009 0.0022
MR-BMA -0.1263 -0.0889 -0.0625 0.0331 0.0297 0.0240 -0.1739 -0.1468 -0.1309 0.1721 0.1462 0.1301 -0.0006 -0.0012 0.0007
Best model -0.1225 -0.0724 -0.0483 0.0297 0.0251 0.0189 -0.1663 -0.1282 -0.1181 0.1610 0.1286 0.1205 0.0007 -0.0017 -0.0017
Scenario 2: NMR metabolites, d = 92 risk factors
Setting A Setting B
θ = 0.3 θ = 0 θ = 0.3 θ = −0.3 θ = 0
R2 0.1 0.3 0.5 0.1 0.3 0.5 0.1 0.3 0.5 0.1 0.3 0.5 0.1 0.3 0.5
IVW -0.1225 0.0181 0.0218 -0.0309 -0.0039 -0.0122 0.0589 -0.0054 0.0023 0.0006 0.0146 0.0199 -0.00191 -0.00087 -0.00015
Lars -0.2484 -0.2024 -0.1864 0.0038 0.0054 0.0047 -0.2562 -0.2225 -0.2042 0.2576 0.2245 0.2081 0.00045 -0.00014 -0.00012
Lasso -0.2593 -0.2136 -0.1881 0.0051 0.0070 0.0064 -0.2685 -0.2297 -0.2051 0.2655 0.2297 0.2074 0.00014 -0.00009 -0.00001
Elastic Net -0.2534 -0.2170 -0.1947 0.0057 0.0072 0.0064 -0.2620 -0.2285 -0.2072 0.2595 0.2291 0.2097 0.00024 -0.00015 -0.00001
MR-BMA -0.2557 -0.2092 -0.1724 0.0072 0.0078 0.0070 -0.2700 -0.2306 -0.1965 0.2676 0.2307 0.2002 0.00012 0.00010 -0.00012
Best model -0.2542 -0.2026 -0.1626 0.0070 0.0072 0.0068 -0.2696 -0.2272 -0.1937 0.2634 0.2290 0.1973 0.00030 0.00007 -0.00017
Scenario 3: blood cell traits, d = 33 risk factors
Setting A Setting B
θ = 0.3 θ = 0 θ = 0.3 θ = −0.3 θ = 0
R2 0.1 0.3 0.5 0.1 0.3 0.5 0.1 0.3 0.5 0.1 0.3 0.5 0.1 0.3 0.5
IVW -0.0027 -0.0161 -0.0082 -0.0015 -0.0021 0.0018 0.0030 -0.0102 -0.0091 -0.0653 -0.0052 -0.0029 0.0186 0.0125 0.0167
Lars -0.1398 -0.1080 -0.0761 0.0039 0.0042 0.0037 -0.1346 -0.1192 -0.1047 0.1499 0.1173 0.1082 0.0056 0.0125 0.0132
Lasso -0.1222 -0.0974 -0.0786 0.0058 0.0062 0.0049 -0.1606 -0.1407 -0.1240 0.1670 0.1380 0.1256 0.0112 0.0120 0.0125
Elastic Net -0.1279 -0.1033 -0.0901 0.0062 0.0070 0.0064 -0.1573 -0.1394 -0.1225 0.1591 0.1386 0.1235 0.0115 0.0118 0.0126
MR-BMA -0.1057 -0.0637 -0.0427 0.0073 0.0048 0.0029 -0.1623 -0.1332 -0.1370 0.1641 0.1284 0.1393 0.0121 0.0118 0.0121
Best model -0.0898 -0.0493 -0.0310 0.0064 0.0036 0.0021 -0.1591 -0.1272 -0.0999 0.1615 0.1196 0.1053 0.0126 0.0120 0.0119
Supplementary Table 1: Mean bias of the simulation study (1000 repetitions) for setting A (including four risk factors with
positive causal effect θ = 0.3 and zero causal effect otherwise) and setting B (including four risk factors with positive causal
effect θ = 0.3 and four risk factor with negative causal effect θ = −0.3 and zero causal effect otherwise). The data scenarios
are: Scenario 1: NMR metabolites, d = 12 risk factors, Scenario 2: NMR metabolites, d = 92 risk factors, Scenario 3: blood
cell traits, d = 33 risk factors.
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2  Supplementary Tables
Scenario 1: NMR metabolites, d = 12 risk factors
θ = 0.3 θ = 0
R2 0.1 0.3 0.5 0.1 0.3 0.5
IVW 0.3014 (0.8469) 0.2901 (0.4177) 0.3011 (0.2898) -0.0023 (0.8066) 0.0042 (0.4051) -0.0007 (0.2750)
Lars 0.1504 (0.3855) 0.1946 (0.2353) 0.2257 (0.1914) 0.0143 (0.3289) 0.0179 (0.1829) 0.0142 (0.1531)
Lasso 0.1663 (0.2660) 0.2136 (0.1889) 0.2372 (0.1504) 0.0241 (0.2139) 0.0235 (0.1458) 0.0195 (0.1029)
Elastic Net 0.1771 (0.2752) 0.2151 (0.1753) 0.2359 (0.1407) 0.0263 (0.2343) 0.0247 (0.1593) 0.0213 (0.1091)
MR-BMA 0.1737 (0.2087) 0.2111 (0.1632) 0.2375 (0.1351) 0.0331 (0.1419) 0.0297 (0.0904) 0.0240 (0.0641)
Best model 0.1775 (0.3202) 0.2276 (0.2282) 0.2517 (0.1662) 0.0297 (0.2191) 0.0251 (0.1365) 0.0189 (0.0897)
Scenario 2: NMR metabolites, d = 92 risk factors
θ = 0.3 θ = 0
R2 0.1 0.3 0.5 0.1 0.3 0.5
IVW 0.1775 (4.8910) 0.3181 (2.5256) 0.3218 (1.6537) -0.0309 (4.8750) -0.0039 (2.4965) -0.0122 (1.6604)
Lars 0.0516 (0.2159) 0.0976 (0.1936) 0.1136 (0.1576) 0.0038 (0.2026) 0.0054 (0.1484) 0.0047 (0.0848)
Lasso 0.0407 (0.1091) 0.0864 (0.1262) 0.1119 (0.1311) 0.0051 (0.0575) 0.0070 (0.0468) 0.0064 (0.0402)
Elastic Net 0.0466 (0.1071) 0.0830 (0.1094) 0.1053 (0.1110) 0.0057 (0.0658) 0.0072 (0.0435) 0.0064 (0.0335)
MR-BMA 0.0443 (0.1107) 0.0908 (0.1345) 0.1276 (0.1420) 0.0072 (0.0436) 0.0078 (0.0369) 0.0070 (0.0325)
Best model 0.0458 (0.1887) 0.0974 (0.1977) 0.1374 (0.1951) 0.0070 (0.0899) 0.0072 (0.0737) 0.0068 (0.0629)
Scenario 3: blood cell traits, d = 33 risk factors
θ = 0.3 θ = 0
R2 0.1 0.3 0.5 0.1 0.3 0.5
IVW 0.2973 (1.3937) 0.2839 (0.6799) 0.2918 (0.4254) -0.0015 (1.2552) -0.0021 (0.6499) 0.0018 (0.4162)
Lars 0.1602 (0.6386) 0.1920 (0.3588) 0.2239 (0.2404) 0.0039 (0.5788) 0.0042 (0.3341) 0.0037 (0.2146)
Lasso 0.1778 (0.1826) 0.2026 (0.1336) 0.2214 (0.1156) 0.0058 (0.1080) 0.0062 (0.0613) 0.0049 (0.0429)
Elastic Net 0.1721 (0.1672) 0.1967 (0.1250) 0.2099 (0.1063) 0.0062 (0.1136) 0.0070 (0.0690) 0.0064 (0.0477)
MR-BMA 0.1943 (0.1463) 0.2363 (0.1187) 0.2573 (0.0956) 0.0073 (0.0545) 0.0048 (0.0366) 0.0029 (0.0263)
Best model 0.2102 (0.2163) 0.2507 (0.1521) 0.2690 (0.1146) 0.0064 (0.0835) 0.0036 (0.0471) 0.0021 (0.0335)
Supplementary Table 2: Mean and standard deviation (in round brackets) of the causal effect estimate from the simulation
study (1000 repetitions) for Setting A (including four risk factors with positive causal effect θ = 0.3 and zero causal effect
otherwise). The data scenarios are: Scenario 1: NMR metabolites, d = 12 risk factors, Scenario 2: NMR metabolites, d = 92
risk factors, Scenario 3: blood cell traits, d = 33 risk factors.
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Scenario 1: NMR metabolites, d = 12 risk factors
θ = 0.3 θ = −0.3 θ = 0
R2 0.1 0.3 0.5 0.1 0.3 0.5 0.1 0.3 0.5
IVW 0.2871 (0.777) 0.3012 (0.384) 0.2985 (0.250) -0.2937 (0.752) -0.2995 (0.406) -0.3031 (0.245) 0.0072 (0.785) 0.0035 (0.417) 0.0066 (0.258)
Lars 0.1258 (0.380) 0.1769 (0.238) 0.2108 (0.196) -0.1272 (0.365) -0.1770 (0.251) -0.2096 (0.185) 0.0014 (0.361) -0.0001 (0.210) -0.0011 (0.151)
Lasso 0.1322 (0.336) 0.1970 (0.220) 0.2270 (0.176) -0.1348 (0.274) -0.1962 (0.215) -0.2294 (0.177) 0.0010 (0.266) -0.0009 (0.187) 0.0025 (0.140)
Elastic Net 0.1530 (0.354) 0.2039 (0.212) 0.2336 (0.171) -0.1555 (0.296) -0.2038 (0.208) -0.2354 (0.168) 0.0000 (0.305) 0.0009 (0.193) 0.0022 (0.142)
MR-BMA 0.1261 (0.198) 0.1532 (0.170) 0.1691 (0.160) -0.1279 (0.199) -0.1538 (0.170) -0.1699 (0.162) -0.0006 (0.146) -0.0012 (0.098) 0.0007 (0.079)
Best model 0.1337 (0.297) 0.1718 (0.225) 0.1819 (0.191) -0.1390 (0.297) -0.1714 (0.225) -0.1795 (0.190) 0.0007 (0.215) -0.0017 (0.143) -0.0017 (0.107)
Scenario 2: NMR metabolites, d = 92 risk factors
θ = 0.3 θ = −0.3 θ = 0
R2 0.1 0.3 0.5 0.1 0.3 0.5 0.1 0.3 0.5
IVW 0.3589 (4.858) 0.2946 (2.534) 0.3023 (1.545) -0.2994 (4.512) -0.2854 (2.358) -0.2801 (1.609) -0.0019 (4.834) -0.0009 (2.398) -0.0002 (1.575)
Lars 0.0438 (0.171) 0.0775 (0.169) 0.0958 (0.152) -0.0424 (0.171) -0.0755 (0.169) -0.0919 (0.149) 0.0005 (0.161) -0.0001 (0.126) -0.0001 (0.097)
Lasso 0.0315 (0.107) 0.0703 (0.122) 0.0949 (0.130) -0.0345 (0.108) -0.0703 (0.123) -0.0926 (0.128) 0.0001 (0.060) -0.0001 (0.054) 0.0000 (0.049)
Elastic Net 0.0380 (0.098) 0.0715 (0.111) 0.0928 (0.116) -0.0405 (0.105) -0.0709 (0.110) -0.0903 (0.113) 0.0002 (0.058) -0.0002 (0.049) 0.0000 (0.045)
MR-BMA 0.0300 (0.097) 0.0694 (0.127) 0.1035 (0.139) -0.0324 (0.099) -0.0693 (0.126) -0.0998 (0.136) 0.0001 (0.043) 0.0001 (0.041) -0.0001 (0.037)
Best model 0.0304 (0.150) 0.0728 (0.174) 0.1063 (0.173) -0.0366 (0.170) -0.0710 (0.172) -0.1027 (0.172) 0.0003 (0.085) 0.0001 (0.074) -0.0002 (0.063)
Scenario 3: blood cell traits, d = 33 risk factors
θ = 0.3 θ = −0.3 θ = 0
R2 0.1 0.3 0.5 0.1 0.3 0.5 0.1 0.3 0.5
IVW 0.3030 (1.463) 0.2898 (0.779) 0.2909 (0.479) -0.3653 (1.527) -0.3052 (0.810) -0.3029 (0.508) 0.0066 (1.528) 0.0005 (0.783) 0.0047 (0.507)
Lars 0.1654 (0.762) 0.1808 (0.379) 0.1953 (0.297) -0.1501 (0.766) -0.1827 (0.461) -0.1918 (0.304) -0.0064 (0.762) 0.0005 (0.394) 0.0012 (0.274)
Lasso 0.1394 (0.206) 0.1593 (0.164) 0.1760 (0.149) -0.1330 (0.188) -0.1620 (0.167) -0.1744 (0.149) -0.0008 (0.159) 0.0000 (0.105) 0.0005 (0.078)
Elastic Net 0.1427 (0.218) 0.1606 (0.156) 0.1775 (0.139) -0.1409 (0.206) -0.1614 (0.158) -0.1765 (0.143) -0.0005 (0.184) -0.0002 (0.109) 0.0006 (0.087)
MR-BMA 0.1377 (0.177) 0.1668 (0.150) 0.1630 (0.151) -0.1359 (0.173) -0.1716 (0.155) -0.1607 (0.149) 0.0001 (0.096) -0.0002 (0.072) 0.0001 (0.053)
Best model 0.1409 (0.266) 0.1728 (0.203) 0.2001 (0.180) -0.1385 (0.252) -0.1804 (0.204) -0.1947 (0.177) 0.0006 (0.160) 0.0000 (0.102) -0.0001 (0.078)
Supplementary Table 3: Mean and standard deviation (in round brackets) of the causal effect estimate from the simulation
study (1000 repetitions) for Setting B (including four risk factors with positive causal effect θ = 0.3 and four risk factor with
negative causal effect θ = −0.3 and zero causal effect otherwise). The data scenarios are: Scenario 1: NMR metabolites, d = 12
risk factors, Scenario 2: NMR metabolites, d = 92 risk factors, Scenario 3: blood cell traits, d = 33 risk factors.
22
A) Model averaging
risk factor MIP θ̂MACE
1 LDL.D 0.527 -0.229
2 XS.VLDL.TG 0.247 -0.124
3 S.HDL.TG 0.236 -0.101
4 IDL.TG 0.213 -0.108
5 XXL.VLDL.TG 0.188 0.095
6 S.VLDL.TG 0.175 -0.070
7 S.LDL.C 0.137 0.059
8 Serum.TG 0.137 -0.062
9 Est.C 0.097 0.030
10 XL.HDL.C 0.085 0.021
B) Individual models
risk factor(s) PP θ̂γ
1 LDL.D,S.HDL.TG 0.062 -0.376,-0.398
2 LDL.D,S.VLDL.TG 0.052 -0.485,-0.379
3 LDL.D,Serum.TG 0.020 -0.454,-0.365
4 S.HDL.TG 0.019 -0.433
5 Est.C,IDL.TG 0.019 0.393,-0.625
6 LDL.D,XS.VLDL.TG 0.018 -0.339,-0.324
7 XS.VLDL.TG 0.017 -0.373
8 LDL.D,M.VLDL.TG 0.014 -0.545,-0.408
9 S.HDL.TG,XXL.VLDL.TG 0.013 -0.653,0.45
10 IDL.TG 0.009 -0.343
Supplementary Table 4: Ranking of risk factors (top ten) for age-related macular
degeneration including all variants
Ranking of risk factors (top ten) for age-related macular degeneration
according to their marginal inclusion probability (MIP) A) and the best ten
individual models (sets of risk factors) according to their posterior probability
(PP) B). Calculation is based on all genetic variants n = 148 including the
LIPC region. θ̂γ is the causal effect estimate for a specific model and θ̂MACE is
the model averaged causal effect of a risk factor.
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rs region q M1 q M2 q M3 max q
1 rs6859 APOE 17.007 17.388 17.132 17.388
2 rs492602 FUT2 15.526 13.899 14.591 15.526
3 rs4465830 ZNF335 7.395 11.127 14.223 14.223
4 rs174532 MYRF 11.939 11.078 11.517 11.939
5 rs6489818 MAPKAPK5 11.226 10.857 10.68 11.226
6 rs103294 AC245884.7 8.857 9.255 9.504 9.504
7 rs3817588 GCKR 7.263 8.095 8.411 8.411
8 rs261342 LIPC 7.11 8.107 5.747 8.107
9 rs903319 SLC2A2 8.06 6.567 6.276 8.06
10 rs2587534 AL160408.6 6.498 6.063 6.999 6.999
11 rs2710642 EHBP1 6.662 6.955 6.538 6.955
12 rs9491696 RSPO3 6.317 5.658 5.966 6.317
13 rs1689797 LINC01344 4.638 5.325 6.079 6.079
14 rs6882076 TIMD4 5.742 4.023 3.706 5.742
15 rs8176720 ABO 5.415 4.972 5.334 5.415
16 rs688 LDLR 4.85 5.178 4.694 5.178
17 rs1781930 AKR1C8P 4.978 4.585 4.445 4.978
18 rs702485 DAGLB 4.863 3.892 4.335 4.863
19 rs38855 MET 4.636 3.896 4.858 4.858
20 rs2925979 CMIP 4.66 4.516 4.243 4.66
21 rs7703051 HMGCR 4.581 3.988 3.928 4.581
22 rs2602836 ADH5 3.724 4.357 4.528 4.528
23 rs3741414 INHBC 3.873 4.434 4.158 4.434
24 rs4148218 ABCG8 3.967 3.592 3.666 3.967
25 rs3822072 FAM13A 3.549 3.858 3.811 3.858
26 rs5880 CETP 1.127 2.123 3.679 3.679
27 rs6680658 GALNT2 3.124 3.675 3.457 3.675
28 rs9930333 FTO 3.351 3.428 3.04 3.428
29 rs7225700 THCAT158 3.127 3.305 3.381 3.381
30 rs217386 NPC1L1 1.959 3.311 2.665 3.311
Supplementary Table 5: This table displays the 30 variants with the largest
maximum q and the region they fall in based on all n = 148 genetic variants
for the best individual model 1 (M1: LDL.D and S.HDL.TG), model 2 (M2:
LDL.D and S.VLDL.TG), and model 3 (M3: LDL.D and Serum.TG) and the
maximum q of each variant in all models used for diagnostics.
24
rs region Cd M1 Cd M2 Cd M3 max Cd
1 rs261342 LIPC 0.989 1.087 0.871 1.087
2 rs4465830 ZNF335 0.188 0.108 0.056 0.188
3 rs3817588 GCKR 0.058 0.085 0.105 0.105
4 rs6859 APOE 0.081 0.076 0.087 0.087
5 rs5880 CETP 0.056 0.071 0.081 0.081
6 rs174532 MYRF 0.062 0.062 0.061 0.062
7 rs686030 TTC39B 0.054 0.04 0.052 0.054
8 rs7703051 HMGCR 0.039 0.045 0.05 0.05
9 rs103294 AC245884.7 0.045 0.044 0.044 0.045
10 rs10401969 SUGP1 0.009 0.025 0.043 0.043
11 rs1689797 LINC01344 0.037 0.031 0.026 0.037
12 rs2710642 EHBP1 0.031 0.033 0.03 0.033
13 rs2587534 AL160408.6 0.02 0.018 0.024 0.024
14 rs10493326 DOCK7 0.011 0.017 0.023 0.023
15 rs894210 intergenic 0.015 0.022 0.02 0.022
16 rs6882076 TIMD4 0.006 0.016 0.02 0.02
17 rs903319 SLC2A2 0.02 0.008 0.007 0.02
18 rs515135 APOB(intergenic) 0.019 0.011 0.012 0.019
19 rs799160 intergenic 0.017 0.016 0.019 0.019
20 rs3741414 INHBC 0.01 0.016 0.013 0.016
21 rs1515110 NR 0.014 0.01 0.007 0.014
22 rs1800562 HFE 0.01 0.012 0.012 0.012
23 rs2068888 CYP26A1 0.012 0.011 0.011 0.012
24 rs7225700 THCAT158 0.011 0.012 0.012 0.012
25 rs492602 FUT2 0.011 0.002 0.005 0.011
26 rs38855 MET 0.008 0.003 0.01 0.01
27 rs688 LDLR 0.007 0.01 0.006 0.01
28 rs6680658 GALNT2 0.005 0.01 0.009 0.01
29 rs3198697 PDXDC1 0.007 0.01 0.01 0.01
30 rs2326077 intergenic 0.006 0.006 0.01 0.01
threshold 0.696 0.696 0.696
Supplementary Table 6: This table displays the 30 variants with the largest
maximum Cook’s distance (Cd) and the region they fall based on all n = 148
genetic variants including LIPC for the best individual model 1 (M1: LDL.D
and S.HDL.TG), model 2 (M2: LDL.D and S.VLDL.TG), and model 3 (M3:
LDL.D and Serum.TG). The final line gives the suggested cut-off for Cook’s
distance and variants with Cd above this threshold are given in bold.
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risk factor MIP θ̂MACE
1 XL.HDL.C 0.700 0.344
2 L.HDL.C 0.229 0.087
3 HDL.D 0.087 0.022
4 XS.VLDL.TG 0.082 -0.019
5 LDL.D 0.074 -0.018
6 IDL.TG 0.066 -0.012
7 XXL.VLDL.TG 0.063 0.018
8 S.VLDL.TG 0.062 -0.014
9 Serum.TG 0.061 -0.014
10 Serum.C 0.054 -0.011
11 HDL.C 0.051 0.009
12 M.HDL.C 0.048 -0.010
13 S.HDL.TG 0.047 -0.006
14 XL.HDL.TG 0.045 0.005
15 M.VLDL.C 0.043 -0.005
16 S.VLDL.C 0.043 -0.005
17 ApoA1 0.040 -0.007
18 M.VLDL.TG 0.039 0.006
19 ApoB 0.038 -0.004
20 L.VLDL.C 0.038 -0.005
21 XL.VLDL.TG 0.034 -0.003
22 L.VLDL.TG 0.033 -0.001
23 S.LDL.C 0.033 0.001
24 LDL.C 0.031 -0.003
25 IDL.C 0.029 -0.001
26 SM 0.027 -0.003
27 VLDL.D 0.027 0.002
28 Tot.FA 0.026 -0.001
29 Est.C 0.026 0.001
30 TotPG 0.026 -0.002
Supplementary Table 7: Ranking of risk factors for age-related macular degen-
eration according to their marginal inclusion probability (MIP) after excluding
genetic variants in the LIPC, FUT2 and APOE region (n = 145). Abbre-
viations: MIP=marginal inclusion probability, MACE=model-averaged causal
effect.
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rs region Q M1 Q M2 Q M3 Q M4 Q M5 max Q
1 rs103294 AC245884.7 13.03 13.155 11.936 11.203 14.449 14.449
2 rs6489818 MAPKAPK5 11.244 9.575 10.53 10.356 9.883 11.244
3 rs6882076 TIMD4 9.536 9.118 6.708 6.503 10.504 10.504
4 rs2587534 AL160408.6 5.931 8.936 6.551 6.735 8.409 8.936
5 rs903319 SLC2A2 7.514 6.651 7.275 7.255 6.379 7.514
6 rs3817588 GCKR 4.698 6.3 7.015 6.495 7.051 7.051
7 rs1689797 LINC01344 6.403 4.747 4.635 4.587 5.648 6.403
8 rs8176720 ABO 3.929 6.312 4.592 4.734 5.197 6.312
9 rs38855 MET 3.768 5.98 5.082 4.973 5.205 5.98
10 rs9491696 RSPO3 5.651 5.974 5.017 4.971 5.479 5.974
11 rs7703051 HMGCR 5.974 3.24 3.246 3.319 4.009 5.974
12 rs688 LDLR 2.562 5.557 3.97 4.071 4.856 5.557
13 rs5880 CETP 5.433 2.877 2.687 2.73 4.246 5.433
14 rs1781930 AKR1C8P 5.176 4.259 4.996 5.072 4.851 5.176
15 rs3822072 FAM13A 5.105 3.376 4.504 4.606 4.099 5.105
16 rs2923084 AMPD3 5.067 2.814 2.956 2.944 3.933 5.067
17 rs9693857 AC022784.6 4.752 3.147 3.966 4.246 3.601 4.752
18 rs2710642 EHBP1 3.632 3.432 4.381 4.714 3.318 4.714
19 rs174532 MYRF 2.708 4.701 3.405 3.927 4.12 4.701
20 rs6680658 GALNT2 3.216 3.885 3.926 3.527 3.577 3.926
21 rs686030 TTC39B 1.58 3.558 1.7 1.393 3.913 3.913
22 rs702485 DAGLB 3.569 3.439 3.887 3.768 3.597 3.887
23 rs9930333 FTO 3.872 2.154 3.299 3.245 2.299 3.872
24 rs17789218 intergenic 3.72 2.12 3.145 3.219 3.512 3.72
25 rs2068888 CYP26A1 3.714 1.944 2.47 2.627 2.291 3.714
26 rs9686661 C5orf67 3.702 1.258 2.31 2.597 1.811 3.702
27 rs2297374 SLC22A1 3.294 2.614 2.716 2.554 3.608 3.608
28 rs2925979 CMIP 3.135 3.14 3.417 3.486 3.142 3.486
29 rs3741414 INHBC 2.203 2.149 3.335 3.438 1.8 3.438
30 rs7264396 FER1L4 2.74 3.251 2.562 2.372 3.438 3.438
Supplementary Table 8: This table displays the 30 variants with the largest
maximum q-statistic and the region they fall in based on n = 145 genetic vari-
ants after excluding LIPC, FUT2 and APOE for the best individual model
1 (M1: XL.HDL.C), model 2 (M2: L.HDL.C), model 3 (M3: XL.HDL.C and
XS.VLDL.TG), model 4 (M4: IDL.TG and XL.HDL.C), model 5 (M5: HDL.D),
and the maximum q-statistic of each variant in all models used for diagnostics.
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rs region Cd M1 Cd M2 Cd M3 Cd M4 Cd M5 max Cd
1 rs4465830 ZNF335 0.216 0.311 0.106 0.113 0.271 0.311
2 rs5880 CETP 0.234 0.277 0.122 0.122 0.297 0.297
3 rs1689797 LINC01344 0.061 0.098 0.047 0.048 0.086 0.098
4 rs686030 TTC39B 0.072 0.062 0.04 0.033 0.062 0.072
5 rs6882076 TIMD4 0.004 0.001 0.061 0.07 0.016 0.07
6 rs3817588 GCKR 0.005 0 0.062 0.037 0.005 0.062
7 rs174532 MYRF 0.052 0.027 0.039 0.057 0.039 0.057
8 rs13107325 SLC39A8 0.001 0.032 0.001 0 0.056 0.056
9 rs7703051 HMGCR 0.001 0.027 0.05 0.048 0.019 0.05
10 rs903319 SLC2A2 0.047 0.025 0.024 0.024 0.021 0.047
11 rs894210 intergenic 0.008 0.046 0.023 0.011 0.018 0.046
12 rs10773105 SCARB1 0.015 0.042 0.009 0.008 0.04 0.042
13 rs103294 AC245884.7 0.028 0.026 0.023 0.039 0.009 0.039
14 rs998584 VEGFA(intergenic) 0 0.039 0.005 0.002 0.013 0.039
15 rs17789218 intergenic 0.034 0.003 0.017 0.017 0.031 0.034
16 rs1800961 HNF4A 0.015 0.033 0.013 0.014 0.011 0.033
17 rs2923084 AMPD3 0.001 0.009 0.03 0.031 0.002 0.031
18 rs688 LDLR 0.005 0.011 0.025 0.029 0.004 0.029
19 rs2587534 AL160408.6 0.026 0 0.018 0.021 0.001 0.026
20 rs1515110 NR 0.008 0.025 0.012 0.008 0.016 0.025
21 rs7897379 REEP3 0.017 0.018 0.013 0.009 0.024 0.024
22 rs10493326 DOCK7 0.003 0.017 0.021 0.014 0.004 0.021
23 rs499974 RN7SL786P 0.016 0.021 0.009 0.009 0.018 0.021
24 rs9491696 RSPO3 0.016 0.013 0.01 0.011 0.02 0.02
25 rs3741414 INHBC 0.003 0.002 0.016 0.019 0.001 0.019
26 rs9686661 C5orf67 0.013 0.002 0.017 0.014 0 0.017
27 rs38855 MET 0 0.014 0.017 0.015 0.005 0.017
28 rs2602836 ADH5 0.016 0.011 0.011 0.011 0.016 0.016
29 rs2278236 ANGPTL4 0.01 0.015 0.005 0.005 0.01 0.015
30 rs702485 DAGLB 0.013 0.014 0.008 0.007 0.014 0.014
0.457 0.457 0.697 0.697 0.457
Supplementary Table 9: This table displays the 30 variants with the largest maximum Cook’s distance (Cd) and the region
they fall in based on n = 145 genetic variants after excluding LIPC, FUT2 and APOE for the best individual model 1 (M1:
XL.HDL.C), model 2 (M2: L.HDL.C), model 3 (M3: XL.HDL.C and XS.VLDL.TG), model 4 (M4: IDL.TG and XL.HDL.C),
model 5 (M5: HDL.D), the final line gives the suggested cut-off for Cook’s distance and this time, there are no variants with
Cd above this threshold.
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p = 0.01
# risk factor MIP θ̂MACE
1 XL.HDL.C 0.608 0.308
2 L.HDL.C 0.283 0.109
3 HDL.D 0.087 0.030
4 HDL.C 0.024 0.008
5 XS.VLDL.TG 0.011 -0.002
6 IDL.TG 0.009 -0.002
7 S.HDL.TG 0.009 -0.002
8 LDL.D 0.007 -0.002
9 Serum.C 0.007 -0.001
10 S.VLDL.TG 0.007 -0.001
p = 0.05
# risk factor MIP θ̂MACE
1 XL.HDL.C 0.663 0.330
2 L.HDL.C 0.249 0.095
3 HDL.D 0.084 0.026
4 XS.VLDL.TG 0.047 -0.010
5 IDL.TG 0.040 -0.007
6 LDL.D 0.037 -0.008
7 HDL.C 0.035 0.008
8 S.VLDL.TG 0.032 -0.006
9 Serum.C 0.030 -0.005
10 Serum.TG 0.029 -0.006
p = 0.1
# risk factor MIP θ̂MACE
1 XL.HDL.C 0.70 0.34
2 L.HDL.C 0.23 0.09
3 HDL.D 0.09 0.02
4 XS.VLDL.TG 0.08 -0.02
5 LDL.D 0.07 -0.02
6 IDL.TG 0.07 -0.01
7 S.VLDL.TG 0.06 -0.01
8 XXL.VLDL.TG 0.06 0.02
9 Serum.TG 0.06 -0.01
10 Serum.C 0.05 -0.01
p = 0.2
# risk factor MIP θ̂MACE
1 XL.HDL.C 0.700 0.344
2 L.HDL.C 0.229 0.087
3 HDL.D 0.087 0.022
4 XS.VLDL.TG 0.082 -0.019
5 LDL.D 0.075 -0.018
6 IDL.TG 0.067 -0.013
7 S.VLDL.TG 0.062 -0.014
8 XXL.VLDL.TG 0.061 0.018
9 Serum.TG 0.061 -0.014
10 Serum.C 0.053 -0.010
p = 0.3
# risk factor MIP θ̂MACE
1 XL.HDL.C 0.675 0.315
2 L.HDL.C 0.302 0.126
3 XXL.VLDL.TG 0.300 0.121
4 LDL.D 0.244 -0.073
5 Serum.TG 0.212 -0.065
6 XS.VLDL.TG 0.197 -0.052
7 S.VLDL.TG 0.190 -0.053
8 M.VLDL.TG 0.173 0.048
9 Serum.C 0.165 -0.053
10 ApoA1 0.152 -0.038
Supplementary Table 10: Parameter check for the prior probability p, ranging
from p = 0.01 to p = 0.3. This reflects 0.3 to 9 expected causal risk factors. The
main analysis used p = 0.1 reflecting an a priori expected number of 3 causal risk




# risk factor MIP θ̂MACE
1 XL.HDL.C 0.52 0.13
2 L.HDL.C 0.42 0.09
3 HDL.D 0.27 0.05
4 LDL.D 0.15 -0.02
5 HDL.C 0.14 0.02
6 XS.VLDL.TG 0.13 -0.02
7 S.HDL.TG 0.13 -0.02
8 S.VLDL.TG 0.11 -0.01
9 IDL.TG 0.10 -0.01
10 Serum.TG 0.09 -0.01
σ = 0.3
# risk factor MIP θ̂MACE
1 XL.HDL.C 0.69 0.32
2 L.HDL.C 0.25 0.09
3 XS.VLDL.TG 0.11 -0.02
4 HDL.D 0.11 0.03
5 LDL.D 0.10 -0.02
6 IDL.TG 0.08 -0.01
7 S.VLDL.TG 0.08 -0.02
8 XXL.VLDL.TG 0.08 0.02
9 Serum.TG 0.07 -0.01
10 S.HDL.TG 0.06 -0.01
σ = 0.5
# risk factor MIP θ̂MACE
1 XL.HDL.C 0.70 0.34
2 L.HDL.C 0.23 0.09
3 HDL.D 0.09 0.02
4 XS.VLDL.TG 0.08 -0.02
5 LDL.D 0.07 -0.02
6 IDL.TG 0.07 -0.01
7 S.VLDL.TG 0.06 -0.01
8 XXL.VLDL.TG 0.06 0.02
9 Serum.TG 0.06 -0.01
10 Serum.C 0.05 -0.01
σ = 0.7
# risk factor MIP θ̂MACE
1 XL.HDL.C 0.69 0.35
2 L.HDL.C 0.23 0.09
3 HDL.D 0.08 0.02
4 XS.VLDL.TG 0.07 -0.02
5 LDL.D 0.06 -0.01
6 IDL.TG 0.05 -0.01
7 S.VLDL.TG 0.05 -0.01
8 Serum.TG 0.05 -0.01
9 XXL.VLDL.TG 0.05 0.02
10 Serum.C 0.05 -0.01
Supplementary Table 11: Parameter check for the prior variance σ2, ranging
from σ = 0.1 to σ = 0.7. The main analysis used σ = 0.5. Abbreviations:
MIP=marginal inclusion probability, MACE=model-averaged causal effect.
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risk factor beta p−value
1 Serum.C -2.033 0.004
2 LDL.C -1.808 0.014
3 IDL.C 2.156 0.014
4 XXL.VLDL.TG 1.075 0.015
5 M.VLDL.TG 1.769 0.019
6 LDL.D -0.937 0.032
7 S.LDL.C 1.302 0.064
8 S.VLDL.C 1.046 0.066
9 L.HDL.C 1.350 0.129
10 S.HDL.TG 0.562 0.175
11 SM -0.221 0.223
12 VLDL.D -0.497 0.250
13 ApoA1 -0.390 0.318
14 XS.VLDL.TG -1.015 0.330
15 M.VLDL.C -0.856 0.339
16 Tot.FA 0.350 0.359
17 L.VLDL.TG -0.616 0.371
18 TotPG -0.246 0.470
19 Serum.TG -0.771 0.525
20 XL.VLDL.TG -0.302 0.605
21 IDL.TG 0.398 0.654
22 ApoB 0.273 0.658
23 L.VLDL.C -0.241 0.670
24 M.HDL.C 0.098 0.814
25 Est.C 0.082 0.828
26 HDL.C -0.193 0.838
27 XL.HDL.TG 0.083 0.850
28 XL.HDL.C 0.079 0.868
29 S.VLDL.TG 0.066 0.932
30 HDL.D -0.029 0.958
Supplementary Table 12: Ranking of risk factors for age-related macular de-
generation using inverse-variance weighted (IVW) regression according to their
p−value after excluding genetic variants in the LIPC, FUT2 and APOE region
n = 145. Abbreviations: beta=causal effect, p=p-value of the causal effect (not
adjusted for multiple testing).
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Supplementary Table 13: Ranking of risk factors for age-related macular de-
generation using Lars regression according to their L1 regularised causal effect
estimate after excluding genetic variants in the LIPC, FUT2 and APOE region
n = 145. Abbreviations: beta L1=L1 regularised causal effect.
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Supplementary Table 14: Ranking of risk factors for age-related macular degen-
eration using Lasso regression (L1 penalty) according to their regularised causal
effect estimate after excluding genetic variants in the LIPC, FUT2 and APOE
region n = 145. Abbreviations: beta L1=L1 regularised causal effect.
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Supplementary Table 15: Ranking of risk factors for age-related macular degen-
eration using Elastic Net regression (L1+L2 penalty) according to their regu-
larised causal effect estimate after excluding genetic variants in the LIPC, FUT2




Derivation of Bayes factors for a set of risk factors
In this note, we derive a closed form expression for the Bayes factor that quan-
tifies the evidence for a particular model (one risk factor or set ofmultiple risk
factors) to have a causal effect on the outcome compared to the Null model,
which includes no risk factor and no intercept.
Building on the 2-sample MR approach [1] our work is based on summarised
data, where genetic variants are used as instrumental variables. In univariable
MR, we observe for each genetic variant i = 1, ..., n the association of variant i
with the risk factor X measured by the beta-coefficient βXi from a univariable
regression where the genetic variant i is regressed on the risk factor X, and the
association of variant i with the outcome Y measured by the beta-coefficient
βYi where the genetic variant i is regressed on the outcome Y, respectively. The
causel effect θ of risk factor X on Y can be estimated using the IVW estimate
or equivalently the following weighted regression without an intercept
βYi = θβXi + εi, εi ∼ N (0, se(βYi)2). (1)
The same causal effect θ can be derived using a 2-stage least squares approach
[2]. In fact, the beta-coefficients are estimates of the genetic association, but we
omit the ”hat” notation and treat the beta-coefficient as observations. A further
assumption for this approach is that the genetic variants are independent (or
uncorrelated) which can be controlled in the selection process of the genetic
variants. Extension for correlated variants are for example described in [2].
In order to consider multiple risk factors jointly in one model multivariable
MR was introduced in [3]. In the following, we consider j = 1, ..., d risk factors.
Assume βX = {βX1 , ...,βXd} to be a matrix of dimension n × d, where d is
the number of risk factors and n is the number of genetic variants. Again each
individual element βXi,j of the predictor matrix is derived from a univariable
regression where the genetic variant i is regressed on the risk factor Xj . Multi-
variable MR can be cast as a weighted linear multivariable regression model
βYi = θ1βXi1 + θ2βXi2 + . . .+ θdβXid + εi, εi ∼ N (0, se(βYi)2), (2)
where the dependent variable is the association with the outcome βY measured
on i = 1, ...., n instrumental variables and the predictors are the j = 1, ..., d
genetic associations with the d risk factors. In matrix notation this can be
written as
βY = βXθ + ε, ε ∼ N (0, se(βY)2). (3)
In other words, the risk factors represent the variable space and the genetic
variants used as instrumental variables are treated as observations. In practise,
we standardise each observation of both, βYi and βXi by dividing by se(βYi)
before the analysis and we assume in the following derivations that βY and βX
are standardised.
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We use Bayes factors [4] in order to quantify the evidence for a particular
model. By model we refer to the set of risk factors which have a causal effect
on the outcome of interest. In order to formalise which risk factors are part of
a specific model Mγ and consequently have a causal effect on the outcome we
introduce a binary indicator γ of length d that indicates which risk factors are
selected and which ones are not
γj =
{
1, if the jth risk factor is selected,
0 otherwise.
(4)
The indicator γ encodes a specific regression model Mγ that includes the risk
factors as indicated in γ. Accordingly, we define βXγ as the design matrix of
the risk factors included and θγ as the respective causal effects.
The computation of the Bayes factor for model Mγ against the Null model
M0, i.e. including no risk factor and no intercept, as presented in the Methods
section of the main article requires two ingredients: First the marginal proba-
bility of βY given βXγ of model Mγ and second, the marginal probability of
βY given the Null model M0, which we derive as follows:
1. pγ(βY | βXγ ): the marginal probability of βY given βXγ
In order to model the correlation between risk factors we base our likeli-
hood on a multivariate Gaussian distribution




Following Servin and Stephens’ D2 prior [5] we use the following conjugate
prior assumptions for the causal effects θγ , the residual ε and the precision
τ
θγ | τ ∼ N(0,ν/τ),
ε ∼ N(0, 1
τ
),
τ ∼ Γ(κ/2, λ/2), (6)
where A | B is defined as A conditional on B. Further we can derive
analytically the joint posterior distribution for θγ and τ as
τ | βY,βXγ ∼ Γ((n+ κ)/2, 1/2(β
t
Y βY −ΘtΩ−1Θ + λ)),




















Next we integrate out the causal effects θγ . To begin with, we sort the
equation so that the integral contains only terms dependent on θγ
pγ(βY | βXγ , τ) =
∫ ∞
−∞
pγ(βY | βXγ ,θγ , τ)pγ(θγ | τ)




















− τ2 (θγ − Θ)tΩ
−1(θγ − Θ)
}
















































where ‖X‖ denotes the determinant of a matrix X and ∞ infinity. Note
that the final line in the integral can be simplified to
− 2θtγ(A − D) + θ
t
γ(B − C)θγ , (9)
where
A = βtXγβY
B = (βtXγβXγ − ν
−1)
C = Ω−1
D = Ω−1Θ (10)
By completing the square in θγ and integrating out θγ the final integral
equals 1.
Overall, this simplifies to












Next we integrate out the precision τ
pγ(βY | βXγ ) =
∫ ∞
0




















The above integral is the normalisation constant of a Gamma distribution
with shape α = (n+κ)2 and rate β =
1
2 (βY
tβY −ΘtΩ−1Θ + λ). Thus the
above simplifies exactly to
















tβY −ΘtΩ−1Θ + λ)
}−(n+κ)
2 . (14)
2. p0(βY): the marginal probability of βY given the Null model M0
Next, we derive the marginal probability of the Null model, i.e. where no







with an expectation fixed at zero, which is a consequence of the missing
intercept.




















Again the above integral is the normalisation constant of a Gamma dis-
tribution with shape α = (n+κ)2 and rate β0 =
1
2 (βY


















The Bayes factor for model Mγ against M0 is defined as the ratio of the
marginal probability of βY given model Mγ (13) over the marginal probability
of βY given the Null model (17)
BF (Mγ) =
























Next we consider the limit as κ, λ → 0. κ and λ are the shape and scale
parameter of the Gamma Distribution, which is the conjugate distribution for
38
precision. In the limiting case the expectation of the error precision would
converge towards a point mass at zero. A precision that converges to zero
translates into an error variance that converges to infinity. Thus the limiting
case represents a dominant error noise and no variance explained by the model,
which is a conservative prior assumption. Moreover, the limit λ → 0 leads to
the invariance property of the posterior for θ, ie the posterior of θ changes
appropriately with shifts and scaling (for example inverse-variance weighting)
operations on βY.











These Bayes factors are then used in the model averaging to quantify the
evidence for a model and together with the prior are used to evaluate which
model or set of risk factors has the largest support to have a causal effect on
the outcome.
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